Alimera Sciences INC: insider trades · United States · SEC (Form 4)

About Alimera Sciences INC

Alimera Sciences Inc. is a U.S.-based biopharmaceutical company historically focused on ophthalmology and listed on the NASDAQ market in the United States (United States) under the ticker ALIM until its acquisition by ANI Pharmaceuticals in September 2024. The company was founded in 2003 and built its identity around the development, commercialization, and label expansion of therapies for chronic retinal disease. Its U.S. headquarters had been in Alpharetta, Georgia, which served as its operational and commercial base for many years. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/0001267602-24-000019-index.htm?utm_source=openai)) Alimera’s core business centered on ILUVIEN, a fluocinolone acetonide intravitreal implant designed to provide long-acting drug delivery inside the eye. The product was developed for diabetic macular edema (DME) and, in certain markets, for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The company also developed commercial rights around YUTIQ, another ophthalmology asset used in uveitis, reinforcing its expertise in a specialized area with high clinical, regulatory, and commercial barriers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/alim-20231231x10k.htm?utm_source=openai)) From a competitive standpoint, Alimera was a focused niche player rather than a diversified large-cap pharma company. That specialization helped it cultivate strong relationships with retina specialists and ophthalmologists treating chronic retinal disorders, where differentiation depends on durability, patient convenience, and clinical value rather than scale alone. Historically, the company also built an international footprint, with ILUVIEN commercialized in the United States and in multiple overseas markets, including Europe and parts of the Middle East. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1267602/000126760224000019/alim-20231231x10k.htm?utm_source=openai)) Recent developments have been dominated by ownership change. ANI Pharmaceuticals completed its acquisition of Alimera on September 16, 2024, bringing ILUVIEN and YUTIQ into its broader portfolio. In 2025, ANI disclosed that the FDA approved an expanded U.S. label for ILUVIEN to include NIU-PS, broadening the product’s commercial opportunity. Recent clinical presentations also highlighted comparative data for ILUVIEN in diabetic macular edema, supporting the ongoing evidence package around the asset. For investors, ALIM represents a former niche ophthalmology platform whose standalone equity story has effectively transitioned into a portfolio asset within ANI Pharmaceuticals, with value now driven by execution, label expansion, and commercial monetization rather than independent public-company growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1023024/000102302424000088/anipclosing-20240916xexx991.htm?utm_source=openai))